HDAC-IN-42 (compound 14f) is a highly potent and selective inhibitor of histone deacetylase (HDAC) enzymes, with IC50 values of 0.19 μM for HDAC1 and 4.98 μM for HDAC6. It exhibits significant anticancer properties, inhibiting cell proliferation, inducing apoptosis, and causing cell cycle arrest specifically at the G2/M phase [1].

HDAC-IN-42 (compound 14f) demonstrates anti-proliferative effects on various cancer cell lines, with C50s of 9.56 μM for MCF-7, 13.32 μM for HCT-116, 10.46 μM for HepG2, and 6.91 μM for HeLa cells. At 1, 5, and 10 μM over 24 hours, it reduces colony formation in HeLa cells and increases histone H3 and α-tubulin expression, indicating effects on cell structure and genetic material packaging. HDAC-IN-42 induces apoptosis and arrests the cell cycle at the G2/M phase after 48 hours, highlighting its potential as a targeted therapeutic agent [1].